Cefiderocol

Pre-clinicalCompleted

1 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Gram-Negative Infection

Conditions

Gram-Negative Infection

Trial Timeline

Jul 31, 2022 → Jun 16, 2023

NCT ID

NCT05789199

About Cefiderocol

Cefiderocol is a pre-clinical stage product being developed by Shionogi for Gram-Negative Infection. The current trial status is completed. This product is registered under clinical trial identifier NCT05789199. Target conditions include Gram-Negative Infection.

What happened to similar drugs?

0 of 2 similar drugs in Gram-Negative Infection were approved

Approved (0) Terminated (1) Active (1)

❌Ceftolozane-Tazobactam + MeropenemMerckPhase 3

🔄tigecyclinePfizerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03780140	Pre-clinical	Completed	—	—	Bacterial Infections
NCT07465432	Approved	Recruiting	Feb 16, 2026	Feb 28, 2027	Drug Clearance After Severe Burn Injury
NCT05789199	Pre-clinical	Completed	Jul 31, 2022	Jun 16, 2023	Gram-Negative Infection
NCT05373615	Phase 1	Completed	Jul 25, 2022	Nov 20, 2024	Pharmacokinetics
NCT05314764	Approved	Completed	Jun 1, 2022	Dec 11, 2024	Cystic Fibrosis
NCT04995835	Phase 1	Completed	Jul 16, 2021	Sep 1, 2024	Sepsis
NCT03869437	Phase 2	Completed	Oct 28, 2019	Jan 29, 2024	Bloodstream Infections

Competing Products

14 competing products in Gram-Negative Infection

See all competitors

Product	Company	Stage	Hype Score
Cefiderocol + Standard of Care	Shionogi	Phase 2	35
Cefiderocol + Standard of Care	Shionogi	Phase 2	35
Cefiderocol + Standard of Care	Shionogi	Phase 2	35
HRS-8427	Jiangsu Hengrui Medicine	Phase 1	29
Part A: ATM-AVI Single Dose, Cohorts 1-4 + Part B: Multiple-dose ATM-AVI, Cohorts 1-4	AbbVie	Phase 2	42
IMI/REL + Active Control + Oral Switch	Merck	Phase 2/3	38
IMI/REL FDC	Merck	Phase 1	29
Ceftolozane-Tazobactam + Meropenem	Merck	Phase 3	32
Ceftolozane/Tazobactam 1000/500 mg + Ceftolozane/Tazobactam 30/15 mg/kg + Ceftolozane/Tazobactam 20/10 mg/kg + Ceftolozane/Tazobactam 18/9 mg/kg + Ceftolozane/Tazobactam 12/6 mg/kg	Merck	Phase 1	29
nacubactam + meropenem	Roche	Phase 1	29
Part A: Single Dose Ceftazidime-Avibactam, Cohorts 1-3 + Part B: Multiple-dose Ceftazidime-Avibactam, Cohorts 1-3	Pfizer	Phase 2	27
ATM-AVI + BAT	Pfizer	Phase 2	42
tigecycline	Pfizer	Phase 3	40
AN3365 + Placebo	Pfizer	Phase 1	29